Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
Go back to Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)| (NASDAQ: XENE) | Delayed: 39.88 -0.43 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.31 | 52 Week High | $9.75 | |||
| Open | $40.48 | 52 Week Low | $5.65 | |||
| Day High | $41.26 | P/E | N/A | |||
| Day Low | $39.01 | EPS | $0.00 | |||
| Volume | 362,875 | |||||
